Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP441 in Participants With Narcolepsy Type 1
NCT06961266Phase 1Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JZP441 in narcolepsy type 1 (NT1) (4 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Mean sleep latency of the first 4 sessions of the Maintenance of Wakefulness Test at 7 hours. Started May 2025; status: terminated.
02
Drugs
JZP441
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT06961266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961266.